AxoGen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXGN research report →
Companywww.axogeninc.com
AxoGen, Inc. , together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
- CEO
- Michael D. Dale
- IPO
- 1986
- Employees
- 451
- HQ
- Alachua, FL, US
Price Chart
Valuation
- Market Cap
- $2.27B
- P/E
- -70.02
- P/S
- 9.53
- P/B
- 9.00
- EV/EBITDA
- 387.80
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.01%
- Op Margin
- -3.79%
- Net Margin
- -13.21%
- ROE
- -20.74%
- ROIC
- -3.40%
Growth & Income
- Revenue
- $225.21M · 20.21%
- Net Income
- $-15,703,000 · -57.60%
- EPS
- $-0.34 · -47.83%
- Op Income
- $-7,849,000
- FCF YoY
- -26763.64%
Performance & Tape
- 52W High
- $45.83
- 52W Low
- $9.22
- 50D MA
- $36.41
- 200D MA
- $27.58
- Beta
- 1.17
- Avg Volume
- 1.07M
Get TickerSpark's AI analysis on AXGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Wendell Amy McBride | other | 1,647 |
| May 8, 26 | Wendell Amy McBride | sell | 1,647 |
| May 8, 26 | Wendell Amy McBride | other | 1,647 |
| May 7, 26 | JOHNSON JOHN | other | 11,050 |
| May 7, 26 | JOHNSON JOHN | sell | 11,050 |
| May 7, 26 | JOHNSON JOHN | other | 11,050 |
| May 7, 26 | Weiler Kathy Johnson | other | 16,344 |
| May 7, 26 | Weiler Kathy Johnson | other | 16,344 |
| May 7, 26 | Weiler Kathy Johnson | sell | 16,344 |
| May 7, 26 | Kemp Jens | sell | 4,000 |
Our AXGN Coverage
We haven't published any research on AXGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AXGN Report →